Health Trials

KRAS G12C Mutations

2

Review clinical trials related to KRAS G12C Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Participants needed: 31
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 26, 2026Locations: 2
Eligibility criteria

Histologically confirmed diagnosis of advanced/metastatic microsatellite stable... [+25]

Prior PD1 or CTLA4 inhibition therapy [+17]

Read more
Status: Not yet recruiting

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor? * What happens to KQB368 in the body? Participants will: * Take KQB368 orally daily in 21-day cycles * Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that

Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kumquat Biosciences Inc.Updated: Apr 21, 2026
Eligibility criteria

Histologically confirmed diagnosis of a solid tumor [+6]

Read more